Nivolumab-induced myocardial necrosis in a patient with lung cancer: A case report | Zendy

Takashi Sakai | Zendy; Kazuyuki Yahagi | Zendy; Tatsuhiro Hoshino | Zendy; Toshiya Yokota | Zendy; Kengo Tanabe | Zendy; Masaya Mori | Zendy; Shingo Ikeda | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nivolumab-induced myocardial necrosis in a patient with lung cancer: A case report

Author(s) -

Takashi Sakai,

Kazuyuki Yahagi,

Tatsuhiro Hoshino,

Toshiya Yokota,

Kengo Tanabe,

Masaya Mori,

Shingo Ikeda

Publication year - 2019

Publication title -

respiratory medicine case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.42

H-Index - 14

ISSN - 2213-0071

DOI - 10.1016/j.rmcr.2019.100839

Subject(s) - medicine , nivolumab , ejection fraction , cardiology , heart failure , necrosis , lung cancer , adenocarcinoma , cancer , immunotherapy

A 74-year-old man with lung adenocarcinoma recurrence was admitted to our hospital because of dyspnea 7 days after receiving initial immunotherapy with nivolumab. Electrocardiography revealed ST-segment elevation in V1-6 and echocardiography showed a markedly reduced left ventricular ejection fraction of 9% and akinesis of the anteroseptal wall and apex. He died from acute heart failure 3 days after admission. Microscopically, multiple small foci of myocardial necrosis with few inflammatory cells were scattered in both ventricles. Obstruction of the coronary artery was not identified. We believed that the cause of death was acute heart failure possibly due to nivolumab-induced myocardial necrosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research